You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Recommendations for the Care of Cancer Survivors*

Table 2.  

General Symptoms of Cancer Survivors (Not Related to Specific Cancer or Treatment)

Table 3.  

Symptoms Most Common After Treatment of Rectal Cancer*

CME

The Challenges of Colorectal Cancer Survivorship

  • Authors: Crystal S. Denlinger, MD; Andrea M. Barsevick, RN, PhD
  • CME Released: 9/21/2009
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/21/2010
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care physicians, gastroenterologists, surgeons, radiation oncologists, and other physicians who care for patients with a history of colorectal cancer.

The goal of this activity is to describe common symptoms among survivors of colorectal cancer and the management of these patients.

Upon completion of this activity, participants will be able to:

  1. Analyze the prognosis of colorectal cancer (CRC)
  2. Identify the most common symptom among survivors of CRC
  3. Distinguish emotional concerns among survivors of CRC
  4. Describe long-term symptoms related to the treatment of CRC


Disclosures

As an organization accredited by the ACCME, MedscapeCME requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

MedscapeCME encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Crystal S. Denlinger, MD

    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Crystal S. Denlinger, MD, has disclosed that she has received research funding from Merrimack Pharmaceuticals for phase 1 clinical trials and from Genentech, Inc. for unrelated clinical trials.

  • Andrea M. Barsevick, RN, PhD

    Department of Nursing, Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Andrea M. Barsevick, RN, PhD, has disclosed no relevant financial relationships.

Editor(s)

  • Kerrin G. Robinson, MA

    Medical/Scientific Editor, Journal of the National Comprehensive Cancer Network

    Disclosures

    Disclosure: Kerrin G. Robinson, MA, has disclosed no relevant financial relationships.

CME Author(s)

  • Charles P. Vega, MD, FAAFP

    Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

    Disclosures

    Disclosure: Charles P. Vega, MD, FAAFP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of MedscapeCME and JNCCN - The Journal of the National Comprehensive Cancer Network.

    MedscapeCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    MedscapeCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. MedscapeCME encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

The Challenges of Colorectal Cancer Survivorship: Late and Long-Term Effects of Treatment

processing....

Late and Long-Term Effects of Treatment

Oxaliplatin-Induced Peripheral Neuropathy

Recent studies of long-term CRC survivors have begun to address the late and long-term effects of newer treatment regimens (Table 3). Oxaliplatin-induced peripheral neuropathy has become a common and occasionally dose-limiting toxicity in the CRC survivor population, usually manifesting as sensory impairment of the peripheral nerves in a stocking-glove distribution. Symptoms of numbness, pain, paresthesias, dysesthesias, and changes in proprioception may affect fine motor skills, such as writing, holding objects, buttoning shirts, picking up coins, and walking. Rarely, urinary retention and Lhermitte's sign (electric-shock sensation shooting down spine with neck flexion) can occur.[42-44] Symptoms most commonly appear after cumulative doses of oxaliplatin exceeding 780 mg/m[2], and are most likely caused by oxaliplatin accumulation in the dorsal root ganglia, with interference of calcium-dependent voltage-gated sodium channels by oxalate, a metabolite of oxaliplatin.[42,43,45-48]

In the adjuvant setting, up to 92% of survivors treated with oxaliplatin and infusional 5-FU (FOLFOX) or bolus 5-FU (FLOX) developed some degree of sensory neuropathy, with 8% to 12% developing severe neuropathy interfering with function (grade 3) and 22% requiring premature discontinuation of oxaliplatin for severe neuropathy.[49,50] Although most survivors have improvement or recovery of nerve function within 1 month of discontinuation of treatment, the median time to resolution of symptoms was approximately 9 months.[51] Furthermore, 20% of survivors may have experienced a worsening of their symptoms after treatment discontinuation and up to 12% had persistent symptoms 4 years after completion of adjuvant treatment.[7,51] Therefore, persistent numbness, tingling, and cold-induced pain may be a long-term problem in a small subset of survivors.[52]

Measures to prevent or treat oxaliplatin-induced neuropathy are needed. In the metastatic setting, limited evidence shows that glutamine, reduced glutathione, alpha-lipoic acid, and oxcarbazepine may reduce the incidence and severity of sensory neuropathy, whereas gabapentin and carbamazepine have not been shown to be effective.[53-58] A retrospective evaluation of calcium and magnesium infusions before and after oxaliplatin infusion suggested a reduction in chronic neuropathy without compromising chemotherapy efficacy, although this has not been confirmed in randomized prospective studies.[59,60] In the adjuvant setting, the use of intravenous calcium gluconate and magnesium sulfate pre- and post-oxaliplatin infusion decreased the incidence of grade 2 neurotoxicity compared with placebo (28% vs. 58%; P = .01),[61] although the study was stopped prematurely because of initial concerns regarding lower tumor response with the same intervention in the metastatic setting.[62] Nonsteroidal anti-inflammatory medications, opioids, and referral to neurology or pain management for persistent symptoms may be useful, although their efficacy is unknown.[44]

Bowel Dysfunction

Chronic diarrhea is reported by 13% to 50% of patients up to 10 years after treatment, with rectal cancer patients more likely than colon cancer patients to report diarrhea (24% vs. 10%; P = .04).[18,32,63] Diarrhea has been associated with limitations in activity and can negatively affect QOL.[18,32] Survivors who underwent an anterior resection reported a median of 3 bowel movements per day, frequency, urgency, evacuatory difficulties, and inability to differentiate stool and gas. These symptoms were most problematic during the first year after resection and were associated with fear, poor body image, and low self-confidence.[38,64]

Both pre- and postoperative radiation for rectal cancer increases the risk for long-term bowel dysfunction. Preoperative short-course radiation (5 Gy in 5 fractions) has been associated with a 2.5-fold higher rate of small bowel obstruction and 2-fold higher incidence of abdominal pain compared with those not treated in this manner, and increased bowel frequency and limitations in activities of daily living and social activities up to 5 years after treatment.[41,65,66] Postoperative radiation also results in frequent bowel movements, similar to survivors who undergo preoperative radiation, and is associated, up to 5 years after treatment, with clustering of bowel movements (42%), increase in nighttime bowel movements (46%), incontinence (39%), pad wearing (41%), and inability to defer defecation (78%).[67,68] Long-term anorectal dysfunction after radiation, including reduced reservoir capacity, can persist at 10 years.[69]

Treatment for bowel problems after CRC treatment typically includes antidiarrheal medications, bulk-forming agents, use of undergarment pads, and diet manipulation.[64] Elimination of specific foods (e.g., fats and oils, meat, milk products, raw vegetables, fibrous foods) and the use of probiotic supplements have had limited benefit.[63,70] Attention to this issue is imperative because survivors may assume abnormal bowel symptoms are an inevitable consequence of treatment and may not address persistent symptoms at follow-up appointments.[63,71]

Pelvic Insufficiency Fractures After Radiation

Bone damage and risk for fractures may be increased after radiotherapy for rectal cancer. A large retrospective study of older women diagnosed with anal, cervical, or rectal cancer showed that survivors of rectal cancer experienced a 65% increase in the cumulative incidence of pelvic fractures after radiation compared with those who were not irradiated (11.2% vs. 8.7%; P < .001), resulting in a possible increase in the absolute lifetime risk for fracture from 17% to 27%. The effect of radiation remained significant after controlling for other risk factors.[72]

The use of combined modality therapy may heighten the effect of radiation on bone density; medications and estrogen deficiency may further contribute to the risk for osteoporosis.[73] Therefore, survivors who have received prior pelvic radiation should undergo long-term monitoring of bone density, appropriate medical treatment of osteopenia and osteoporosis, and careful evaluation if symptoms suggesting fractures develop.

Urogenital Dysfunction

Urinary and sexual dysfunction are known complications of rectal cancer treatment, reported in at least 30% of patients undergoing definitive treatment.[41,74-77] In studies of short-course radiation followed by total mesorectal excision (TME) versus TME alone, symptoms at 5 years included urinary incontinence (38%), difficulties in bladder emptying (31%), need to void within 2 hours of voiding (70%), and need for protective pads (57%).[41,74] Risk factors for postoperative incontinence included preoperative incontinence, female gender, perioperative blood loss, preoperative bladder emptying difficulties, autonomic nerve damage, and presence of a permanent stoma.[40,41,74] Severity of urinary incontinence increased with time, from 18% at 3 months to 31% at 5 years, and contributed to a lower overall perception of health status.[41,74]

Although preservation of autonomic nerves during TME has been shown to minimize permanent sexual dysfunction, abdominoperineal resection has been associated with lower sexual function at 5 years compared with anterior resection (26% vs. 48%; P = .001).[38,78] Men enrolled in a TME trial reported generalized sexual dysfunction (76.4%), erectile dysfunction (79.8%), and ejaculatory problems (72.2%) after surgery. Risk factors included preoperative radiation, presence of a stoma, perioperative blood loss, anastomotic leak, and autonomic nerve damage. Women reported an increase in generalized sexual dysfunction (62%), dyspareunia (59%), and vaginal dryness (56.6%) after treatment. Risk factors included preoperative radiation and the presence of a stoma.[75] Vaginal stenosis can also occur after pelvic radiation and contribute to dyspareunia.[79]

Few intervention trials have targeted urogenital dysfunction in rectal cancer survivors. A study of 32 men undergoing rectal resection for cancer or inflammatory bowel disease showed that 79% of those receiving sildenafil reported reversal or satisfactory improvement in erectile dysfunction versus 13% receiving placebo (P = .0009).[80] The use of vaginal dilators by women undergoing vaginal brachytherapy for cervical cancer has shown benefit in maintaining vaginal patency, and dilators have been used empirically in rectal cancer survivors.[79,81]